An observational study in Nephrolithiasis, Glomerulonephritis, Amyloidosis,AKI, CKD, Tubuli Interstitial and Urinary System Disorders in IBD Patients, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Nephrolithiasis by Assiut University — 4 open to participants now, 4 under way, none of them phase 3. Nephrolithiasis · Assiut University.
Among the 10 studies in Nephrolithiasis by Assiut University, this one is one of 3 that started in 2024, is one of 6 observational ones, and was the 7th registered.
324 studies on the registry are indexed under Nephrolithiasis; 89 are open to participants now.
Browse Nephrolithiasis studies →4 of the 10 studies in Nephrolithiasis by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 18–60
Assiut University
Ages 18+
Assiut University
Ages 18+
Of the 51 Nephrolithiasis studies recruiting now, 30 (59%) set no upper age limit and 14 (27%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 57 observational studies indexed under Nephrolithiasis.
Median enrollment 73 across the 4 interventional studies, 93 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Nephrolithiasis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06720311Assiut UniversityManagement of Medium Sized Renal Stones | 2026-12-31 |
| NCT07753096Assiut UniversityPredicting the Success of Flexible Ureterorenoscopy for Kidney and Upper Ureter Stones | 2027-09 |
| NCT07855068Assiut UniversityEffect of a Low-Dose Ketamine-Dexmedetomidine-Based Opioid-Sparing Anesthesia Protocol on Postoperative Quality of Recovery After Percutaneous Nephrolithotomy | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Nephrolithiasis by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Detection and classification of different renal and urinary affection in patients with IBD that attended to Assist University Hospitals
Background (Research Question, Available Data from the literature, Current strategy for dealing with the problem, Rationale of the research that paves the way to the aim(s) of the work). (200-250 words max.) Inflammatory bowel disease is an idiopathic disease cause sever inflammation of GIT , presentes in ulcerative colitis or Crohn's disease occur in 6%-47%
IBD is profoundly associated with extra intestinal manifestions , Especially renal and urinary involvement occurs in 4% - 23% of patients with IBD.
Patterns of renal complications include nephrolithiasis, glomerulonephritis, amyloidosis, AKl, CKD, tubulointerstitial nephritis, asymptomatic proteinuria and hematuria; each type has specific mechanism
Nephrolithiasis is 10-100 times greater in IBD patients than general population.most common stones are calcium, oxalate and urate; Stones occur due to loss of electrolytes "Mg,k" due to diarrhea which lead to crystallization.
Glomerulonephritis pattern in IBD , is associated with IgA nephropathy, IgM nephropathy, membranous and focal segmental glomerulonephritis.
There is genetic connection between IgA nephropathy and intestinal diseases!
Secondary amyloidosis (AA-type) is a rare but serious complication of IBD.renal amyloidosis had been proven to be the most common lethal manifestion of IBD - associated amyloidosis (A), since renal involvement rapidly leads to end stage renal failure.
Sever long -standing IBD consists a predisposing factor for renal complications that occur in 4-23 % of patients So we aim to shed more light on the pathophysiology of renal damage in IBD; considering the renal manifestions and complications of IBD, it is important to emphasize the role of screening of renal function in preventing, diagnosing, and,if possible, reversing probable kidney damage.
Sample size was calculated by using it open -epi version 3 According to the prevalence of urinary affection in IBD patients 13,5%() Sample size was 92 patient at confidance level 95% +-7 confidance limit
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patterns of renal and urinary involvement in IBD patients
Is renal and urinary system affect on IBD patients ?
Time frame: 2 years
No study locations are listed for this record.
Start is estimated for Aug 2024; primary completion for Sep 2026, 25 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.